{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,6,8]],"date-time":"2025-06-08T18:22:56Z","timestamp":1749406976616},"reference-count":158,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"2","license":[{"start":{"date-parts":[[2018,10,1]],"date-time":"2018-10-01T00:00:00Z","timestamp":1538352000000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2018,10]]},"abstract":"<jats:sec>\n            <jats:title>Abstract<\/jats:title>\n            <jats:p>Nonalcoholic fatty liver disease (NAFLD) is an important cause of chronic hepatic disease and liver transplant in Western societies. The increasing prevalence is related to dietary changes and sedentarism and follows the increasing frequency of obesity and type 2 diabetes mellitus.<\/jats:p>\n            <jats:p>Growing evidence of association of NAFLD with cardiovascular diseases (CVD), independent of cardiovascular risk factors, has prompted the clarification of whether the liver is mainly a key-effector or a target-organ of the metabolic disarrangements in the metabolic syndrome. The therapeutic strategies able to alter liver disease progression and, through this, reduce the cardiovascular risk have also been tested in the last 2 decades.<\/jats:p>\n            <jats:p>This review focus on the possible interactions between hepatic disease, metabolic syndrome, and CVD, and on their implications for clinical practice.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1016\/j.pbj.0000000000000002","type":"journal-article","created":{"date-parts":[[2018,10,2]],"date-time":"2018-10-02T17:35:42Z","timestamp":1538501742000},"page":"e2","source":"Crossref","is-referenced-by-count":6,"title":["NAFLD and cardiovascular disease"],"prefix":"10.1097","volume":"3","author":[{"given":"Elisabete","family":"Martins","sequence":"first","affiliation":[{"name":"Department of Medicine, Faculty of Medicine"},{"name":"Instituto de Investiga\u00e7\u00e3o e Inova\u00e7\u00e3o em Sa\u00fade (i3s), University of Porto"},{"name":"Department of Cardiology"}]},{"given":"Ana","family":"Oliveira","sequence":"additional","affiliation":[{"name":"Department of Nuclear Medicine, S\u00e3o Jo\u00e3o Hospital Center, Porto, Portugal."}]}],"member":"276","reference":[{"key":"R1-20230824","doi-asserted-by":"crossref","first-page":"185","DOI":"10.3748\/wjg.14.185","article-title":"Non-alcoholic fatty liver disease and the metabolic syndrome: an update","volume":"14","author":"Rector","year":"2008","journal-title":"World J Gastroenterol"},{"key":"R2-20230824","doi-asserted-by":"crossref","first-page":"d3897","DOI":"10.1136\/bmj.d3897","article-title":"How big a problem is non-alcoholic fatty liver disease?","volume":"343","author":"Anstee","year":"2011","journal-title":"BMJ"},{"issue":"(suppl 1)","key":"R3-20230824","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1159\/000341127","article-title":"Nonalcoholic fatty liver disease: what the pathologist can tell the clinician","volume":"30","author":"Brunt","year":"2012","journal-title":"Dig Dis"},{"key":"R4-20230824","doi-asserted-by":"crossref","first-page":"752","DOI":"10.2214\/AJR.13.11367","article-title":"Natural history of hepatic steatosis: observed outcomes for subsequent liver and cardiovascular complications","volume":"202","author":"Pickhardt","year":"2014","journal-title":"AJR Am J Roentgenol"},{"key":"R5-20230824","doi-asserted-by":"crossref","first-page":"372","DOI":"10.1016\/j.jhep.2010.04.008","article-title":"A position statement on NAFLD\/NASH based on the EASL 2009 special conference","volume":"53","author":"Ratziu","year":"2010","journal-title":"J Hepatol"},{"key":"R6-20230824","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1007\/s00439-013-1294-3","article-title":"Genome-wide scan revealed that polymorphisms in the PNPLA3, SAMM50, and PARVB genes are associated with development and progression of nonalcoholic fatty liver disease in Japan","volume":"132","author":"Kitamoto","year":"2013","journal-title":"Hum Genet"},{"key":"R7-20230824","doi-asserted-by":"crossref","first-page":"126","DOI":"10.2174\/1574887109666141216111143","article-title":"Non alcoholic fatty liver: epidemiology and natural history","volume":"9","author":"Masarone","year":"2014","journal-title":"Rev Recent Clin Trials"},{"key":"R8-20230824","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1055\/s-0028-1091978","article-title":"The epidemiology of nonalcoholic fatty liver disease: a global perspective","volume":"28","author":"Lazo","year":"2008","journal-title":"Semin Liver Dis"},{"key":"R9-20230824","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1053\/j.gastro.2010.09.038","article-title":"Prevalence of nonalcoholic fatty liver disease and nonalcoholic steatohepatitis among a largely middle-aged population utilizing ultrasound and liver biopsy: a prospective study","volume":"140","author":"Williams","year":"2011","journal-title":"Gastroenterology"},{"key":"R10-20230824","doi-asserted-by":"crossref","first-page":"E462","DOI":"10.1152\/ajpendo.00064.2004","article-title":"Magnetic resonance spectroscopy to measure hepatic triglyceride content: prevalence of hepatic steatosis in the general population","volume":"288","author":"Szczepaniak","year":"2005","journal-title":"Am J Physiol Endocrinol Metab"},{"key":"R11-20230824","doi-asserted-by":"crossref","first-page":"1139","DOI":"10.2337\/dc10-2229","article-title":"Prevalence of and risk factors for hepatic steatosis and nonalcoholic Fatty liver disease in people with type 2 diabetes: the Edinburgh Type 2 Diabetes Study","volume":"34","author":"Williamson","year":"2011","journal-title":"Diabetes Care"},{"key":"R12-20230824","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1111\/j.1478-3231.2008.01718.x","article-title":"Prevalence and associated factors of non-alcoholic fatty liver disease in patients with type-2 diabetes mellitus","volume":"29","author":"Leite","year":"2009","journal-title":"Liver Int"},{"key":"R13-20230824","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1111\/j.1365-2036.2011.04724.x","article-title":"Systematic review: the epidemiology and natural history of non-alcoholic fatty liver disease and non-alcoholic steatohepatitis in adults","volume":"34","author":"Vernon","year":"2011","journal-title":"Aliment Pharmacol Ther"},{"key":"R14-20230824","first-page":"275","article-title":"Liver pathology in diabetes mellitus and morbid obesity. Clinical, pathological, and biochemical considerations","volume":"24","author":"Silverman","year":"1989","journal-title":"Pathol Annu"},{"key":"R15-20230824","doi-asserted-by":"crossref","first-page":"1048","DOI":"10.1016\/S1542-3565(04)00440-9","article-title":"Nonalcoholic fatty liver disease: a review of current understanding and future impact","volume":"2","author":"Charlton","year":"2004","journal-title":"Clin Gastroenterol Hepatol"},{"key":"R16-20230824","doi-asserted-by":"crossref","first-page":"2005","DOI":"10.1002\/hep.25762","article-title":"The diagnosis and management of non-alcoholic fatty liver disease: practice Guideline by the American Association for the Study of Liver Diseases, American College of Gastroenterology, and the American Gastroenterological Association","volume":"55","author":"Chalasani","year":"2012","journal-title":"Hepatology"},{"key":"R17-20230824","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1097\/00042737-200603000-00002","article-title":"Prevalence of liver steatosis in patients with chronic hepatitis B: a study of associated factors and of relationship with fibrosis","volume":"18","author":"Thomopoulos","year":"2006","journal-title":"Eur J Gastroenterol Hepatol"},{"key":"R18-20230824","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1016\/j.cld.2013.07.012","article-title":"Drug-induced steatohepatitis","volume":"17","author":"Patel","year":"2013","journal-title":"Clin Liver Dis"},{"key":"R19-20230824","doi-asserted-by":"crossref","first-page":"1130","DOI":"10.1007\/s00535-005-1711-z","article-title":"Diagnosing autoimmune hepatitis in nonalcoholic fatty liver disease: is the International Autoimmune Hepatitis Group scoring system useful?","volume":"40","author":"Yatsuji","year":"2005","journal-title":"J Gastroenterol"},{"key":"R20-20230824","doi-asserted-by":"crossref","first-page":"e91987","DOI":"10.1371\/journal.pone.0091987","article-title":"Non-invasive assessment of hepatic steatosis in patients with NAFLD using controlled attenuation parameter and 1H-MR spectroscopy","volume":"9","author":"Karlas","year":"2014","journal-title":"PLoS ONE"},{"key":"R21-20230824","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1016\/j.jhep.2009.05.023","article-title":"Non-invasive assessment and quantification of liver steatosis by ultrasound, computed tomography and magnetic resonance","volume":"51","author":"Schwenzer","year":"2009","journal-title":"J Hepatol"},{"key":"R22-20230824","doi-asserted-by":"crossref","first-page":"1082","DOI":"10.1002\/hep.24452","article-title":"Diagnostic accuracy and reliability of ultrasonography for the detection of fatty liver: a meta-analysis","volume":"54","author":"Hernaez","year":"2011","journal-title":"Hepatology"},{"key":"R23-20230824","doi-asserted-by":"crossref","first-page":"1286","DOI":"10.1053\/jhep.2003.50229","article-title":"Clinical and histologic spectrum of nonalcoholic fatty liver disease associated with normal ALT values","volume":"37","author":"Mofrad","year":"2003","journal-title":"Hepatology"},{"key":"R24-20230824","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1016\/j.jhep.2011.03.020","article-title":"Presence and severity of non-alcoholic fatty liver disease in a large prospective primary care cohort","volume":"56","author":"Armstrong","year":"2012","journal-title":"J Hepatol"},{"key":"R25-20230824","doi-asserted-by":"crossref","first-page":"1212","DOI":"10.2337\/dc06-2247","article-title":"Prevalence of nonalcoholic fatty liver disease and its association with cardiovascular disease among type 2 diabetic patients","volume":"30","author":"Targher","year":"2007","journal-title":"Diabetes Care"},{"key":"R26-20230824","doi-asserted-by":"crossref","first-page":"646","DOI":"10.1016\/j.cgh.2011.12.039","article-title":"Independent association between nonalcoholic fatty liver disease and cardiovascular disease in the US population","volume":"10","author":"Stepanova","year":"2012","journal-title":"Clin Gastroenterol Hepatol"},{"key":"R27-20230824","doi-asserted-by":"crossref","first-page":"d6891","DOI":"10.1136\/bmj.d6891","article-title":"Non-alcoholic fatty liver disease and mortality among US adults: prospective cohort study","volume":"343","author":"Lazo","year":"2011","journal-title":"BMJ"},{"key":"R28-20230824","doi-asserted-by":"crossref","first-page":"1413","DOI":"10.1016\/S0016-5085(99)70506-8","article-title":"Nonalcoholic fatty liver disease: a spectrum of clinical and pathological severity","volume":"116","author":"Matteoni","year":"1999","journal-title":"Gastroenterology"},{"key":"R29-20230824","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1053\/j.gastro.2005.04.014","article-title":"The natural history of nonalcoholic fatty liver disease: a population-based cohort study","volume":"129","author":"Adams","year":"2005","journal-title":"Gastroenterology"},{"key":"R30-20230824","doi-asserted-by":"crossref","first-page":"865","DOI":"10.1002\/hep.21327","article-title":"Long-term follow-up of patients with NAFLD and elevated liver enzymes","volume":"44","author":"Ekstedt","year":"2006","journal-title":"Hepatology"},{"key":"R31-20230824","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1002\/hep.23314","article-title":"Decreased survival of subjects with elevated liver function tests during a 28-year follow-up","volume":"51","author":"Soderberg","year":"2010","journal-title":"Hepatology"},{"key":"R32-20230824","doi-asserted-by":"crossref","first-page":"1249584","DOI":"10.1155\/2013\/124958","article-title":"Independent association between nonalcoholic fatty liver disease and cardiovascular disease: a systematic review and meta-analysis","volume":"2013","author":"Lu","year":"2013","journal-title":"Int J Endocrinol"},{"key":"R33-20230824","doi-asserted-by":"crossref","first-page":"617","DOI":"10.3109\/07853890.2010.518623","article-title":"Meta-analysis: natural history of non-alcoholic fatty liver disease (NAFLD) and diagnostic accuracy of non-invasive tests for liver disease severity","volume":"43","author":"Musso","year":"2011","journal-title":"Ann Med"},{"key":"R34-20230824","doi-asserted-by":"crossref","first-page":"741","DOI":"10.2337\/dc08-1870","article-title":"Alanine aminotransferase, gamma-glutamyltransferase, and incident diabetes: the British Women's Heart and Health Study and meta-analysis","volume":"32","author":"Fraser","year":"2009","journal-title":"Diabetes Care"},{"key":"R35-20230824","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1111\/liv.12912","article-title":"The impact of non-alcoholic fatty liver disease on incident type 2 diabetes mellitus in non-overweight individuals","volume":"36","author":"Fukuda","year":"2016","journal-title":"Liver Int"},{"key":"R36-20230824","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1111\/j.1464-5491.2011.03427.x","article-title":"Increased prevalence of chronic kidney disease in patients with type 1 diabetes and non-alcoholic fatty liver","volume":"29","author":"Targher","year":"2012","journal-title":"Diabet Med"},{"key":"R37-20230824","doi-asserted-by":"crossref","first-page":"1567","DOI":"10.1038\/ajg.2010.18","article-title":"Nonalcoholic fatty liver disease increases risk of death among patients with diabetes: a community-based cohort study","volume":"105","author":"Adams","year":"2010","journal-title":"Am J Gastroenterol"},{"key":"R38-20230824","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1586\/17474124.2014.903798","article-title":"Management of fatty liver disease with the metabolic syndrome","volume":"8","author":"Machado","year":"2014","journal-title":"Expert Rev Gastroenterol Hepatol"},{"key":"R39-20230824","doi-asserted-by":"crossref","first-page":"3143","DOI":"10.1161\/circ.106.25.3143","article-title":"Third report of the National Cholesterol Education Program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (adult treatment panel III) final report","volume":"106","year":"2002","journal-title":"Circulation"},{"key":"R40-20230824","doi-asserted-by":"crossref","first-page":"1721","DOI":"10.1136\/gut.2011.242016","article-title":"Coronary artery disease and cardiovascular outcomes in patients with non-alcoholic fatty liver disease","volume":"60","author":"Wong","year":"2011","journal-title":"Gut"},{"key":"R41-20230824","doi-asserted-by":"crossref","first-page":"750","DOI":"10.1136\/gut.2003.019984","article-title":"Long term prognosis of fatty liver: risk of chronic liver disease and death","volume":"53","author":"Dam-Larsen","year":"2004","journal-title":"Gut"},{"key":"R42-20230824","doi-asserted-by":"crossref","first-page":"1579","DOI":"10.3748\/wjg.v13.i10.1579","article-title":"Nonalcoholic fatty liver disease is a novel predictor of cardiovascular disease","volume":"13","author":"Hamaguchi","year":"2007","journal-title":"World J Gastroenterol"},{"key":"R43-20230824","doi-asserted-by":"crossref","first-page":"1403","DOI":"10.1002\/hep.23135","article-title":"Ultrasonographic hepatic steatosis increases prediction of mortality risk from elevated serum gamma-glutamyl transpeptidase levels","volume":"50","author":"Haring","year":"2009","journal-title":"Hepatology"},{"key":"R44-20230824","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1111\/j.1751-2980.2011.00571.x","article-title":"Natural course of nonalcoholic fatty liver disease in southern China: a prospective cohort study","volume":"13","author":"Zhou","year":"2012","journal-title":"J Dig Dis"},{"key":"R45-20230824","doi-asserted-by":"crossref","first-page":"2729","DOI":"10.1161\/ATVBAHA.107.152298","article-title":"Gamma-glutamyltransferase is associated with incident vascular events independently of alcohol intake: analysis of the British Women's Heart and Health Study and Meta-Analysis","volume":"27","author":"Fraser","year":"2007","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"R46-20230824","doi-asserted-by":"crossref","first-page":"586","DOI":"10.1097\/MCA.0000000000000402","article-title":"Association of coronary artery calcium with bone mineral density in postmenopausal women","volume":"27","author":"Xu","year":"2016","journal-title":"Coron Artery Dis"},{"key":"R47-20230824","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1016\/j.atherosclerosis.2013.07.052","article-title":"A systematic review: burden and severity of subclinical cardiovascular disease among those with nonalcoholic fatty liver; should we care?","volume":"230","author":"Oni","year":"2013","journal-title":"Atherosclerosis"},{"key":"R48-20230824","doi-asserted-by":"crossref","first-page":"600","DOI":"10.1016\/j.jhep.2008.06.012","article-title":"Non-alcoholic fatty liver disease is strongly associated with carotid atherosclerosis: a systematic review","volume":"49","author":"Sookoian","year":"2008","journal-title":"J Hepatol"},{"key":"R49-20230824","doi-asserted-by":"crossref","first-page":"2359","DOI":"10.2337\/dc12-0515","article-title":"Fatty liver, insulin resistance, and features of metabolic syndrome: relationships with coronary artery calcium in 10,153 people","volume":"35","author":"Sung","year":"2012","journal-title":"Diabetes Care"},{"key":"R50-20230824","doi-asserted-by":"crossref","first-page":"1752","DOI":"10.1007\/s10620-009-0935-9","article-title":"Association between nonalcoholic fatty liver disease and coronary artery calcification","volume":"55","author":"Chen","year":"2010","journal-title":"Dig Dis Sci"},{"key":"R51-20230824","doi-asserted-by":"crossref","first-page":"1829","DOI":"10.1515\/CCLM.2010.349","article-title":"Relationship of hepatic steatosis and alanine aminotransferase with coronary calcification","volume":"48","author":"Jung","year":"2010","journal-title":"Clin Chem Lab Med"},{"key":"R52-20230824","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1002\/hep.25593","article-title":"Nonalcoholic fatty liver disease is associated with coronary artery calcification","volume":"56","author":"Kim","year":"2012","journal-title":"Hepatology"},{"key":"R53-20230824","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1148\/radiol.09090769","article-title":"Presence of coronary plaques in patients with nonalcoholic fatty liver disease","volume":"254","author":"Assy","year":"2010","journal-title":"Radiology"},{"key":"R54-20230824","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1016\/j.atherosclerosis.2010.01.049","article-title":"Coronary flow reserve is impaired in patients with nonalcoholic fatty liver disease: association with liver fibrosis","volume":"211","author":"Yilmaz","year":"2010","journal-title":"Atherosclerosis"},{"key":"R55-20230824","doi-asserted-by":"crossref","first-page":"2234","DOI":"10.1253\/circj.CJ-11-1487","article-title":"Impaired myocardial perfusion reserve in patients with fatty liver disease assessed by quantitative myocardial perfusion magnetic resonance imaging","volume":"76","author":"Nakamori","year":"2012","journal-title":"Circ J"},{"key":"R56-20230824","doi-asserted-by":"crossref","first-page":"e104941","DOI":"10.1371\/journal.pone.0104941","article-title":"Association between noninvasive fibrosis markers and cardio-vascular organ damage among adults with hepatic steatosis","volume":"9","author":"Sesti","year":"2014","journal-title":"PLoS ONE"},{"key":"R57-20230824","doi-asserted-by":"crossref","first-page":"1357","DOI":"10.1002\/hep.26156","article-title":"Association between noninvasive fibrosis markers and mortality among adults with nonalcoholic fatty liver disease in the United States","volume":"57","author":"Kim","year":"2013","journal-title":"Hepatology"},{"key":"R58-20230824","doi-asserted-by":"crossref","first-page":"1547","DOI":"10.1002\/hep.27368","article-title":"Fibrosis stage is the strongest predictor for disease-specific mortality in NAFLD after up to 33 years of follow-up","volume":"61","author":"Ekstedt","year":"2015","journal-title":"Hepatology"},{"key":"R59-20230824","doi-asserted-by":"crossref","first-page":"8407","DOI":"10.3748\/wjg.v20.i26.8407","article-title":"Nonalcoholic fatty liver disease and cardiovascular disease","volume":"20","author":"Liu","year":"2014","journal-title":"World J Gastroenterol"},{"key":"R60-20230824","doi-asserted-by":"crossref","first-page":"1325","DOI":"10.2337\/dc06-0135","article-title":"Relations between carotid artery wall thickness and liver histology in subjects with nonalcoholic fatty liver disease","volume":"29","author":"Targher","year":"2006","journal-title":"Diabetes Care"},{"key":"R61-20230824","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1016\/j.cgh.2008.11.005","article-title":"Long-term follow-up of patients with nonalcoholic fatty liver","volume":"7","author":"Rafiq","year":"2009","journal-title":"Clin Gastroenterol Hepatol"},{"key":"R62-20230824","doi-asserted-by":"crossref","first-page":"949","DOI":"10.1097\/01.mcg.0000225668.53673.e6","article-title":"Cardiac abnormalities as a new manifestation of nonalcoholic fatty liver disease: echocardiographic and tissue Doppler imaging assessment","volume":"40","author":"Goland","year":"2006","journal-title":"J Clin Gastroenterol"},{"key":"R63-20230824","first-page":"457","article-title":"Impairment of the left ventricular systolic and diastolic function in patients with non-alcoholic fatty liver disease","volume":"17","author":"Fotbolcu","year":"2010","journal-title":"Cardiol J"},{"key":"R64-20230824","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1016\/j.jhep.2012.11.015","article-title":"Cardiac structure and function are altered in adults with non-alcoholic fatty liver disease","volume":"58","author":"Hallsworth","year":"2013","journal-title":"J Hepatol"},{"key":"R65-20230824","doi-asserted-by":"crossref","first-page":"646","DOI":"10.1016\/j.numecd.2008.12.007","article-title":"Non-alcoholic fatty liver disease is associated with left ventricular diastolic dysfunction in essential hypertension","volume":"19","author":"Fallo","year":"2009","journal-title":"Nutr Metab Cardiovasc Dis"},{"key":"R66-20230824","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1007\/BF03345421","article-title":"Non-alcoholic fatty liver disease is independently associated with left ventricular hypertrophy in hypertensive type 2 diabetic individuals","volume":"35","author":"Mantovani","year":"2012","journal-title":"J Endocrinol Invest"},{"key":"R67-20230824","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1016\/j.jacc.2010.02.049","article-title":"Effects of hepatic triglyceride content on myocardial metabolism in type 2 diabetes","volume":"56","author":"Rijzewijk","year":"2010","journal-title":"J Am Coll Cardiol"},{"key":"R68-20230824","doi-asserted-by":"crossref","first-page":"1690","DOI":"10.1161\/ATVBAHA.112.300556","article-title":"Hepatic steatosis is associated with aortic valve sclerosis in the general population: the Study of Health in Pomerania (SHIP)","volume":"33","author":"Markus","year":"2013","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"R69-20230824","doi-asserted-by":"crossref","first-page":"e88371","DOI":"10.1371\/journal.pone.0088371","article-title":"Nonalcoholic fatty liver disease is associated with aortic valve sclerosis in patients with type 2 diabetes mellitus","volume":"9","author":"Bonapace","year":"2014","journal-title":"PLoS ONE"},{"key":"R70-20230824","doi-asserted-by":"crossref","first-page":"1855","DOI":"10.1161\/ATVBAHA.110.207340","article-title":"Serum gamma-glutamyl transferase and risk of heart failure in the community","volume":"30","author":"Dhingra","year":"2010","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"R71-20230824","doi-asserted-by":"crossref","first-page":"830","DOI":"10.1161\/ATVBAHA.111.240457","article-title":"Gamma-glutamyltransferase, hepatic enzymes, and risk of incident heart failure in older men","volume":"32","author":"Wannamethee","year":"2012","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"R72-20230824","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1016\/j.amjcard.2012.09.021","article-title":"Relation of circulating liver transaminase concentrations to risk of new-onset atrial fibrillation","volume":"111","author":"Sinner","year":"2013","journal-title":"Am J Cardiol"},{"key":"R73-20230824","doi-asserted-by":"crossref","first-page":"e57183","DOI":"10.1371\/journal.pone.0057183","article-title":"Non-alcoholic fatty liver disease is associated with an increased incidence of atrial fibrillation in patients with type 2 diabetes","volume":"8","author":"Targher","year":"2013","journal-title":"PLoS ONE"},{"key":"R74-20230824","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1007\/s10286-009-0031-4","article-title":"Fatigue and autonomic dysfunction in non-alcoholic fatty liver disease","volume":"19","author":"Newton","year":"2009","journal-title":"Clin Auton Res"},{"key":"R75-20230824","doi-asserted-by":"crossref","first-page":"663","DOI":"10.1016\/j.numecd.2014.01.005","article-title":"Association of nonalcoholic fatty liver disease with QTc interval in patients with type 2 diabetes","volume":"24","author":"Targher","year":"2014","journal-title":"Nutr Metab Cardiovasc Dis"},{"key":"R76-20230824","doi-asserted-by":"crossref","first-page":"1038","DOI":"10.1016\/j.metabol.2015.12.012","article-title":"The multiple-hit pathogenesis of non-alcoholic fatty liver disease (NAFLD)","volume":"65","author":"Buzzetti","year":"2016","journal-title":"Metabolism"},{"key":"R77-20230824","doi-asserted-by":"crossref","first-page":"1961","DOI":"10.1002\/hep.23535","article-title":"Increased fructose consumption is associated with fibrosis severity in patients with nonalcoholic fatty liver disease","volume":"51","author":"Abdelmalek","year":"2010","journal-title":"Hepatology"},{"key":"R78-20230824","doi-asserted-by":"crossref","first-page":"434","DOI":"10.1007\/s00535-013-0758-5","article-title":"Mechanisms of hepatic triglyceride accumulation in non-alcoholic fatty liver disease","volume":"48","author":"Kawano","year":"2013","journal-title":"J Gastroenterol"},{"key":"R79-20230824","doi-asserted-by":"crossref","first-page":"1343","DOI":"10.1172\/JCI23621","article-title":"Sources of fatty acids stored in liver and secreted via lipoproteins in patients with nonalcoholic fatty liver disease","volume":"115","author":"Donnelly","year":"2005","journal-title":"J Clin Invest"},{"key":"R80-20230824","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1002\/hep.20280","article-title":"Beyond insulin resistance in NASH: TNF-alpha or adiponectin?","volume":"40","author":"Hui","year":"2004","journal-title":"Hepatology"},{"key":"R81-20230824","doi-asserted-by":"crossref","first-page":"32345","DOI":"10.1074\/jbc.M313478200","article-title":"Mechanism of hepatic insulin resistance in non-alcoholic fatty liver disease","volume":"279","author":"Samuel","year":"2004","journal-title":"J Biol Chem"},{"key":"R82-20230824","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1016\/j.jcmgh.2015.06.011","article-title":"Angiogenesis and fibrogenesis in chronic liver diseases","volume":"1","author":"Bocca","year":"2015","journal-title":"Cell Mol Gastroenterol Hepatol"},{"key":"R83-20230824","doi-asserted-by":"crossref","first-page":"459","DOI":"10.18388\/abp.2016_1252","article-title":"Hepatokines and non-alcoholic fatty liver disease","volume":"63","author":"Lebensztejn","year":"2016","journal-title":"Acta Biochim Pol"},{"key":"R84-20230824","doi-asserted-by":"crossref","first-page":"1279","DOI":"10.1038\/nm.2851","article-title":"Fetuin-A acts as an endogenous ligand of TLR4 to promote lipid-induced insulin resistance","volume":"18","author":"Pal","year":"2012","journal-title":"Nat Med"},{"key":"R85-20230824","doi-asserted-by":"crossref","first-page":"1182","DOI":"10.1038\/nm.2869","article-title":"Fetuin-A: the missing link in lipid-induced inflammation","volume":"18","author":"Heinrichsdorff","year":"2012","journal-title":"Nat Med"},{"key":"R86-20230824","doi-asserted-by":"crossref","first-page":"1363","DOI":"10.1016\/j.jhep.2011.12.025","article-title":"Non-invasive diagnosis of non-alcoholic steatohepatitis by combined serum biomarkers","volume":"56","author":"Shen","year":"2012","journal-title":"J Hepatol"},{"key":"R87-20230824","first-page":"276","article-title":"Increased serum leukocyte cell-derived chemotaxin 2 (LECT2) levels in obesity and fatty liver","volume":"7","author":"Okumura","year":"2013","journal-title":"Biosci Trends"},{"key":"R88-20230824","doi-asserted-by":"crossref","first-page":"2675","DOI":"10.1056\/NEJMc0910143","article-title":"Sex hormone-binding globulin and risk of type 2 diabetes","volume":"361","author":"Stefan","year":"2009","journal-title":"N Engl J Med"},{"key":"R89-20230824","doi-asserted-by":"crossref","first-page":"63","DOI":"10.4093\/dmj.2013.37.1.63","article-title":"Increased selenoprotein p levels in subjects with visceral obesity and nonalcoholic fatty liver disease","volume":"37","author":"Choi","year":"2013","journal-title":"Diabetes Metab J"},{"key":"R90-20230824","article-title":"ANGPTL-8\/betatrophin correlated with hepatocellular lipid content independent of insulin resistance in nonalcoholic fatty liver disease subjects","author":"Hong","year":"2017","journal-title":"J Diabetes Investig"},{"key":"R91-20230824","doi-asserted-by":"crossref","first-page":"e000019","DOI":"10.1136\/bmjgast-2014-000019","article-title":"Systematic review of genetic association studies involving histologically confirmed non-alcoholic fatty liver disease","volume":"2","author":"Wood","year":"2015","journal-title":"BMJ Open Gastroenterol"},{"key":"R92-20230824","doi-asserted-by":"crossref","first-page":"5219","DOI":"10.2174\/13816128113199990381","article-title":"Genetic predisposition in NAFLD and NASH: impact on severity of liver disease and response to treatment","volume":"19","author":"Dongiovanni","year":"2013","journal-title":"Curr Pharm Des"},{"key":"R93-20230824","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1136\/jmg.2009.066597","article-title":"A common variant in the adiponutrin gene influences liver enzyme values","volume":"47","author":"Kollerits","year":"2010","journal-title":"J Med Genet"},{"key":"R94-20230824","doi-asserted-by":"crossref","first-page":"2111","DOI":"10.1194\/jlr.P900013-JLR200","article-title":"A nonsynonymous gene variant in the adiponutrin gene is associated with nonalcoholic fatty liver disease severity","volume":"50","author":"Sookoian","year":"2009","journal-title":"J Lipid Res"},{"key":"R95-20230824","doi-asserted-by":"crossref","first-page":"894","DOI":"10.1002\/hep.23759","article-title":"The association of genetic variability in patatin-like phospholipase domain-containing protein 3 (PNPLA3) with histological severity of nonalcoholic fatty liver disease","volume":"52","author":"Rotman","year":"2010","journal-title":"Hepatology"},{"key":"R96-20230824","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1016\/j.dld.2012.12.006","article-title":"PNPLA3 I148M variant and hepatocellular carcinoma: a common genetic variant for a rare disease","volume":"45","author":"Valenti","year":"2013","journal-title":"Dig Liver Dis"},{"key":"R97-20230824","doi-asserted-by":"crossref","first-page":"2616","DOI":"10.2337\/db09-0279","article-title":"Dissociation between fatty liver and insulin resistance in humans carrying a variant of the patatin-like phospholipase 3 gene","volume":"58","author":"Kantartzis","year":"2009","journal-title":"Diabetes"},{"key":"R98-20230824","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1093\/eurheartj\/ehx662","article-title":"Liver fat content, non-alcoholic fatty liver disease, and ischaemic heart disease: Mendelian randomization and meta-analysis of 279 013 individuals","volume":"39","author":"Lauridsen","year":"2018","journal-title":"Eur Heart J"},{"key":"R99-20230824","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1016\/j.atherosclerosis.2016.12.018","article-title":"Non-alcoholic fatty liver disease and subclinical atherosclerosis: a comparison of metabolically- versus genetically-driven excess fat hepatic storage","volume":"257","author":"Di Costanzo","year":"2017","journal-title":"Atherosclerosis"},{"key":"R100-20230824","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1016\/j.metabol.2016.06.009","article-title":"Non-alcoholic fatty liver disease with and without metabolic syndrome: different long-term outcomes","volume":"66","author":"Karajamaki","year":"2017","journal-title":"Metabolism"},{"key":"R101-20230824","doi-asserted-by":"crossref","first-page":"506","DOI":"10.1002\/hep.27490","article-title":"Transmembrane 6 superfamily member 2 gene variant disentangles nonalcoholic steatohepatitis from cardiovascular disease","volume":"61","author":"Dongiovanni","year":"2015","journal-title":"Hepatology"},{"key":"R102-20230824","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1055\/s-0033-1358525","article-title":"PNPLA3-associated steatohepatitis: toward a gene-based classification of fatty liver disease","volume":"33","author":"Krawczyk","year":"2013","journal-title":"Semin Liver Dis"},{"key":"R103-20230824","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1038\/nrgastro.2013.41","article-title":"Progression of NAFLD to diabetes mellitus, cardiovascular disease or cirrhosis","volume":"10","author":"Anstee","year":"2013","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"R104-20230824","first-page":"187","article-title":"Is NAFLD an independent risk factor for increased IMT in T2DM?","volume":"37","author":"Cakir","year":"2012","journal-title":"Minerva Endocrinol"},{"key":"R105-20230824","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1016\/j.numecd.2016.12.005","article-title":"Translating the biology of adipokines in atherosclerosis and cardiovascular diseases: gaps and open questions","volume":"27","author":"Ruscica","year":"2017","journal-title":"Nutr Metab Cardiovasc Dis"},{"key":"R106-20230824","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1016\/j.jhep.2014.03.013","article-title":"Procoagulant imbalance in patients with non-alcoholic fatty liver disease","volume":"61","author":"Tripodi","year":"2014","journal-title":"J Hepatol"},{"key":"R107-20230824","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1038\/nature11553","article-title":"Genomic approaches to studying the human microbiota","volume":"489","author":"Weinstock","year":"2012","journal-title":"Nature"},{"key":"R108-20230824","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1586\/17474124.2015.965143","article-title":"Diagnosis and management of cardiovascular risk in nonalcoholic fatty liver disease","volume":"9","author":"Lonardo","year":"2015","journal-title":"Expert Rev Gastroenterol Hepatol"},{"key":"R109-20230824","doi-asserted-by":"crossref","first-page":"859","DOI":"10.1016\/j.jhep.2013.05.044","article-title":"From NAFLD in clinical practice to answers from guidelines","volume":"59","author":"Nascimbeni","year":"2013","journal-title":"J Hepatol"},{"key":"R110-20230824","doi-asserted-by":"crossref","first-page":"945","DOI":"10.1111\/j.1478-3231.2011.02753.x","article-title":"The Framingham risk score and heart disease in nonalcoholic fatty liver disease","volume":"32","author":"Treeprasertsuk","year":"2012","journal-title":"Liver Int"},{"key":"R111-20230824","doi-asserted-by":"crossref","first-page":"f1895","DOI":"10.1136\/bmj.f1895","article-title":"When to remeasure cardiovascular risk in untreated people at low and intermediate risk: observational study","volume":"346","author":"Bell","year":"2013","journal-title":"BMJ"},{"key":"R112-20230824","doi-asserted-by":"crossref","first-page":"2748","DOI":"10.1161\/CIR.0b013e3182051bab","article-title":"2010 ACCF\/AHA guideline for assessment of cardiovascular risk in asymptomatic adults: executive summary: a report of the American College of Cardiology Foundation\/American Heart Association Task Force on Practice Guidelines","volume":"122","author":"Greenland","year":"2010","journal-title":"Circulation"},{"key":"R113-20230824","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1016\/j.jhep.2011.06.010","article-title":"Lifestyle interventions for the treatment of non-alcoholic fatty liver disease in adults: a systematic review","volume":"56","author":"Thoma","year":"2012","journal-title":"J Hepatol"},{"key":"R114-20230824","doi-asserted-by":"crossref","first-page":"2156","DOI":"10.2337\/dc10-0856","article-title":"Effect of a 12-month intensive lifestyle intervention on hepatic steatosis in adults with type 2 diabetes","volume":"33","author":"Lazo","year":"2010","journal-title":"Diabetes Care"},{"key":"R115-20230824","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1055\/s-0032-1306428","article-title":"The impact of bariatric surgery on nonalcoholic steatohepatitis","volume":"32","author":"Rabl","year":"2012","journal-title":"Semin Liver Dis"},{"key":"R116-20230824","doi-asserted-by":"crossref","first-page":"510","DOI":"10.1111\/j.1440-1746.2007.04833.x","article-title":"Effects of bariatric surgery on nonalcoholic fatty liver disease: preliminary findings after 2 years","volume":"22","author":"Furuya","year":"2007","journal-title":"J Gastroenterol Hepatol"},{"key":"R117-20230824","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1053\/j.gastro.2015.04.014","article-title":"Bariatric surgery reduces features of nonalcoholic steatohepatitis in morbidly obese patients","volume":"149","author":"Lassailly","year":"2015","journal-title":"Gastroenterology"},{"key":"R118-20230824","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1002\/hep.22575","article-title":"Orlistat for overweight subjects with nonalcoholic steatohepatitis: a randomized, prospective trial","volume":"49","author":"Harrison","year":"2009","journal-title":"Hepatology"},{"key":"R119-20230824","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1016\/j.jhep.2013.02.012","article-title":"The Mediterranean diet improves hepatic steatosis and insulin sensitivity in individuals with non-alcoholic fatty liver disease","volume":"59","author":"Ryan","year":"2013","journal-title":"J Hepatol"},{"key":"R120-20230824","doi-asserted-by":"crossref","first-page":"678","DOI":"10.1016\/j.clnu.2013.08.014","article-title":"Adherence to the Mediterranean diet is associated with the severity of non-alcoholic fatty liver disease","volume":"33","author":"Kontogianni","year":"2014","journal-title":"Clin Nutr"},{"key":"R121-20230824","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1016\/j.nut.2017.02.008","article-title":"Good adherence to the Mediterranean diet reduces the risk for NASH and diabetes in pediatric patients with obesity: the results of an Italian study","volume":"39\u201340","author":"Della Corte","year":"2017","journal-title":"Nutrition"},{"key":"R122-20230824","doi-asserted-by":"crossref","first-page":"468","DOI":"10.1097\/MCO.0b013e3283566614","article-title":"Improving dietary patterns in patients with nonalcoholic fatty liver disease","volume":"15","author":"Carvalhana","year":"2012","journal-title":"Curr Opin Clin Nutr Metab Care"},{"key":"R123-20230824","doi-asserted-by":"crossref","first-page":"1947","DOI":"10.1002\/hep.22292","article-title":"Modest wine drinking and decreased prevalence of suspected nonalcoholic fatty liver disease","volume":"47","author":"Dunn","year":"2008","journal-title":"Hepatology"},{"key":"R124-20230824","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1111\/j.1365-2036.2010.04520.x","article-title":"Alcohol consumption appears to protect against non-alcoholic fatty liver disease","volume":"33","author":"Moriya","year":"2011","journal-title":"Aliment Pharmacol Ther"},{"key":"R125-20230824","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1002\/hep.23711","article-title":"Fitness versus fatness: moving beyond weight loss in nonalcoholic fatty liver disease","volume":"52","author":"Johnson","year":"2010","journal-title":"Hepatology"},{"key":"R126-20230824","doi-asserted-by":"crossref","first-page":"1278","DOI":"10.1136\/gut.2011.242073","article-title":"Resistance exercise reduces liver fat and its mediators in non-alcoholic fatty liver disease independent of weight loss","volume":"60","author":"Hallsworth","year":"2011","journal-title":"Gut"},{"key":"R127-20230824","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1016\/j.jhep.2012.02.023","article-title":"Exercise and non-alcoholic fatty liver disease: a systematic review and meta-analysis","volume":"57","author":"Keating","year":"2012","journal-title":"J Hepatol"},{"key":"R128-20230824","doi-asserted-by":"crossref","first-page":"1287","DOI":"10.1002\/hep.26393","article-title":"Both resistance training and aerobic training reduce hepatic fat content in type 2 diabetic subjects with nonalcoholic fatty liver disease (the RAED2 Randomized Trial)","volume":"58","author":"Bacchi","year":"2013","journal-title":"Hepatology"},{"key":"R129-20230824","doi-asserted-by":"crossref","first-page":"885","DOI":"10.1007\/s00125-011-2446-4","article-title":"Impact of current treatments on liver disease, glucose metabolism and cardiovascular risk in non-alcoholic fatty liver disease (NAFLD): a systematic review and meta-analysis of randomised trials","volume":"55","author":"Musso","year":"2012","journal-title":"Diabetologia"},{"key":"R130-20230824","doi-asserted-by":"crossref","first-page":"2297","DOI":"10.1056\/NEJMoa060326","article-title":"A placebo-controlled trial of pioglitazone in subjects with nonalcoholic steatohepatitis","volume":"355","author":"Belfort","year":"2006","journal-title":"N Engl J Med"},{"key":"R131-20230824","doi-asserted-by":"crossref","first-page":"305","DOI":"10.7326\/M15-1774","article-title":"Long-term pioglitazone treatment for patients with nonalcoholic steatohepatitis and prediabetes or type 2 diabetes mellitus: a randomized trial","volume":"165","author":"Cusi","year":"2016","journal-title":"Ann Intern Med"},{"key":"R132-20230824","doi-asserted-by":"crossref","first-page":"1147","DOI":"10.1053\/j.gastro.2016.01.038","article-title":"Elafibranor, an agonist of the peroxisome proliferator-activated receptor-alpha and -delta, induces resolution of nonalcoholic steatohepatitis without fibrosis worsening","volume":"150","author":"Ratziu","year":"2016","journal-title":"Gastroenterology"},{"key":"R133-20230824","doi-asserted-by":"crossref","first-page":"e50117","DOI":"10.1371\/journal.pone.0050117","article-title":"Improved glycaemia correlates with liver fat reduction in obese, type 2 diabetes, patients given glucagon-like peptide-1 (GLP-1) receptor agonists","volume":"7","author":"Cuthbertson","year":"2012","journal-title":"PLoS ONE"},{"key":"R134-20230824","doi-asserted-by":"crossref","first-page":"1584","DOI":"10.1002\/hep.23569","article-title":"Glucagon-like peptide-1 receptor is present on human hepatocytes and has a direct role in decreasing hepatic steatosis in vitro by modulating elements of the insulin signaling pathway","volume":"51","author":"Gupta","year":"2010","journal-title":"Hepatology"},{"key":"R135-20230824","doi-asserted-by":"crossref","first-page":"819","DOI":"10.1016\/j.cmet.2013.04.008","article-title":"Pharmacology, physiology, and mechanisms of incretin hormone action","volume":"17","author":"Campbell","year":"2013","journal-title":"Cell Metab"},{"key":"R136-20230824","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1111\/cen.12369","article-title":"Glucagon-like peptide-1 analogue, liraglutide, improves liver fibrosis markers in obese women with polycystic ovary syndrome and nonalcoholic fatty liver disease","volume":"81","author":"Kahal","year":"2014","journal-title":"Clin Endocrinol (Oxf)"},{"key":"R137-20230824","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1016\/S0140-6736(15)00803-X","article-title":"Liraglutide safety and efficacy in patients with non-alcoholic steatohepatitis (LEAN): a multicentre, double-blind, randomised, placebo-controlled phase 2 study","volume":"387","author":"Armstrong","year":"2016","journal-title":"Lancet"},{"key":"R138-20230824","doi-asserted-by":"crossref","first-page":"628","DOI":"10.1016\/S0140-6736(15)00982-4","article-title":"A LEAN treatment for non-alcoholic steatohepatitis","volume":"387","author":"Wong","year":"2016","journal-title":"Lancet"},{"key":"R139-20230824","doi-asserted-by":"crossref","first-page":"496453","DOI":"10.1100\/2012\/496453","article-title":"The effectiveness of liraglutide in nonalcoholic fatty liver disease patients with type 2 diabetes mellitus compared to sitagliptin and pioglitazone","volume":"2012","author":"Ohki","year":"2012","journal-title":"ScientificWorldJournal"},{"key":"R140-20230824","doi-asserted-by":"crossref","first-page":"1578","DOI":"10.1210\/jc.2014-3794","article-title":"Effect of vildagliptin on hepatic steatosis","volume":"100","author":"Macauley","year":"2015","journal-title":"J Clin Endocrinol Metab"},{"key":"R141-20230824","doi-asserted-by":"crossref","first-page":"e38744","DOI":"10.1371\/journal.pone.0038744","article-title":"Linagliptin improves insulin sensitivity and hepatic steatosis in diet-induced obesity","volume":"7","author":"Kern","year":"2012","journal-title":"PLoS ONE"},{"key":"R142-20230824","doi-asserted-by":"crossref","first-page":"8341","DOI":"10.3748\/wjg.v20.i26.8341","article-title":"Modern approach to the clinical management of non-alcoholic fatty liver disease","volume":"20","author":"Del Ben","year":"2014","journal-title":"World J Gastroenterol"},{"key":"R143-20230824","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1161\/01.ATV.0000057393.97337.AE","article-title":"Omega-3 fatty acids and cardiovascular disease: new recommendations from the American Heart Association","volume":"23","author":"Kris-Etherton","year":"2003","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"R144-20230824","doi-asserted-by":"crossref","first-page":"1211","DOI":"10.1002\/hep.27289","article-title":"Effects of purified eicosapentaenoic and docosahexaenoic acids in nonalcoholic fatty liver disease: results from the Welcome\u2217 study","volume":"60","author":"Scorletti","year":"2014","journal-title":"Hepatology"},{"key":"R145-20230824","doi-asserted-by":"crossref","first-page":"377.e1","DOI":"10.1053\/j.gastro.2014.04.046","article-title":"No significant effects of ethyl-eicosapentaenoic acid on histologic features of nonalcoholic steatohepatitis in a phase 2 trial","volume":"147","author":"Sanyal","year":"2014","journal-title":"Gastroenterology"},{"key":"R146-20230824","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1097\/MCG.0000000000000099","article-title":"Double-blind randomized placebo-controlled clinical trial of omega 3 fatty acids for the treatment of diabetic patients with nonalcoholic steatohepatitis","volume":"49","author":"Dasarathy","year":"2015","journal-title":"J Clin Gastroenterol"},{"key":"R147-20230824","doi-asserted-by":"crossref","first-page":"1675","DOI":"10.1056\/NEJMoa0907929","article-title":"Pioglitazone, vitamin E, or placebo for nonalcoholic steatohepatitis","volume":"362","author":"Sanyal","year":"2010","journal-title":"N Engl J Med"},{"key":"R148-20230824","doi-asserted-by":"crossref","first-page":"1718","DOI":"10.3748\/wjg.v21.i6.1718","article-title":"Vitamin D: a new player in non-alcoholic fatty liver disease?","volume":"21","author":"Eliades","year":"2015","journal-title":"World J Gastroenterol"},{"key":"R149-20230824","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1007\/s12020-014-0336-5","article-title":"Does vitamin D improve liver enzymes, oxidative stress, and inflammatory biomarkers in adults with non-alcoholic fatty liver disease? A randomized clinical trial","volume":"47","author":"Sharifi","year":"2014","journal-title":"Endocrine"},{"key":"R150-20230824","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1016\/S0140-6736(15)61200-4","article-title":"Trials of obeticholic acid for non-alcoholic steatohepatitis\u2014authors\u2019 reply","volume":"386","author":"Neuschwander-Tetri","year":"2015","journal-title":"Lancet"},{"key":"R151-20230824","doi-asserted-by":"crossref","first-page":"1072","DOI":"10.1002\/hep.28712","article-title":"Farnesoid X receptor activation increases reverse cholesterol transport by modulating bile acid composition and cholesterol absorption in mice","volume":"64","author":"Xu","year":"2016","journal-title":"Hepatology"},{"key":"R152-20230824","doi-asserted-by":"crossref","first-page":"1610","DOI":"10.1002\/hep.24544","article-title":"Pentoxifylline improves nonalcoholic steatohepatitis: a randomized placebo-controlled trial","volume":"54","author":"Zein","year":"2011","journal-title":"Hepatology"},{"key":"R153-20230824","doi-asserted-by":"crossref","first-page":"990","DOI":"10.1097\/MCG.0b013e31819c392e","article-title":"A pilot study using simvastatin in the treatment of nonalcoholic steatohepatitis: a randomized placebo-controlled trial","volume":"43","author":"Nelson","year":"2009","journal-title":"J Clin Gastroenterol"},{"key":"R154-20230824","doi-asserted-by":"crossref","first-page":"1916","DOI":"10.1016\/S0140-6736(10)61272-X","article-title":"Safety and efficacy of long-term statin treatment for cardiovascular events in patients with coronary heart disease and abnormal liver tests in the Greek Atorvastatin and Coronary Heart Disease Evaluation (GREACE) study: a post-hoc analysis","volume":"376","author":"Athyros","year":"2010","journal-title":"Lancet"},{"key":"R155-20230824","doi-asserted-by":"crossref","first-page":"1222","DOI":"10.1002\/hep.20420","article-title":"Therapeutic efficacy of an angiotensin II receptor antagonist in patients with nonalcoholic steatohepatitis","volume":"40","author":"Yokohama","year":"2004","journal-title":"Hepatology"},{"key":"R156-20230824","first-page":"39","article-title":"Therapeutic options in non-alcoholic steatohepatitis (NASH). Are all agents alike? Results of a preliminary study","volume":"16","author":"Georgescu","year":"2007","journal-title":"J Gastrointestin Liver Dis"},{"key":"R157-20230824","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1016\/j.dld.2017.01.147","article-title":"AISF position paper on nonalcoholic fatty liver disease (NAFLD): updates and future directions","volume":"49","year":"2017","journal-title":"Dig Liver Dis"},{"key":"R158-20230824","doi-asserted-by":"crossref","first-page":"15532","DOI":"10.3748\/wjg.v20.i42.15532","article-title":"Liver transplantation and non-alcoholic fatty liver disease","volume":"20","author":"Zezos","year":"2014","journal-title":"World J Gastroenterol"}],"container-title":["Porto Biomedical Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/02054639-201810000-00001","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,8,24]],"date-time":"2023-08-24T01:50:34Z","timestamp":1692841834000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/02054639-201810000-00001"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,10]]},"references-count":158,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2018]]}},"URL":"https:\/\/doi.org\/10.1016\/j.pbj.0000000000000002","relation":{},"ISSN":["2444-8664"],"issn-type":[{"value":"2444-8664","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,10]]}}}